

Recommendations for VoY CCG from York and Scarborough Medicines Commissioning Committee May 2016

	Drug name	Indication	Recommendation	Rationale for recommendation	Place in therapy	RAG status	Potential cost impact
1	Gedarel	Contraception	Approved (correction from last month 2 nd line not 1 st line)	Cost effective branded generic alternative to Mercilon©	2 nd line	Green	No additional costs
2	Guanfacine	Treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 6 to 17.	Approved	Cost effective option for those for whom stimulants are not suitable, not tolerated or have been shown to be ineffective plus for those whom atomoxetine is not suitable, not tolerated or has been shown to be ineffective	3rd line after dexamphetamine/ lisdexamfetamine and atomoxetine has been tried.	RED (to remain as prescribed only by TEVV until a shared care guideline can be considered and approved)	Average cost per year anticipated to be £798 per patient per year. Note that this is similar cost to atomoxetine; no additional new costs anticipated.
3	Sacubitril/Valsartan (Entresto)	Treatment of symptomatic chronic heart failure with reduced ejection fraction	Approved as per NICE guidance NICE TA 388	NICE approved	As an option for treating symptomatic chronic heart failure with reduced ejection fraction as per NICE	To be confirmed – NOT for GP prescribing at present	£95,000 in Year 1 increasing to £475,000 by Year 5 – based on NICE resource impact report.

4	Abiraterone	TA387 : Treatment of metastatic hormone-relapsed prostate cancer before chemotherapy is indicated	Approved	NICE approved; for funding by NHSE	As per NICE TA387	RED	No cost to CCGs - funded by NHSE
5	Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine	TA389 : Treatment of recurrent ovarian cancer	Approved	NICE approved; for funding by NHSE	As per NICE TA389	RED	No cost to CCGs - funded by NHSE
6	Pomalidomide	TA338 Treatment of relapsed and refractory multiple myeloma	Update of commissioning position	Not approved by NICE - negative NICE TA	None	BLACK	No cost

Additional comments:

- Prescribing Guidance for Dry Eye and Corneal Damage/Erosion/Dystrophy was accepted